台股 » 個股 » 國光生 » 籌碼相關 » 券商分點績效

國光生

(4142)
可現股當沖
  • 股價
    27.05
  • 漲跌
    --
  • 漲幅
    0.00%
  • 成交量
    586
  • 產業
    上市 生技醫療類股
  • 633人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
國光生 (4142)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2024/03/27     後一日»

券商獲利排行 - 2024/03/27

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  0.80%23.41.122.4901102026.826.826.927.1
  0.82%4.60.14.51721426.826.826.827.1
  0.76%4.504.52222026.826.8027.1
  0.93%3.703.71515026.826.8027.1
  1.14%3.60.23.51112126.726.726.927.1
  1.31%3.503.51010026.726.7027.1
  0.77%3.32.90.40161526.726.626.827.1
  0.93%2.502.51010026.826.8027.1
  0.93%2.502.51010026.826.8027.1
  0.62%2.502.51515026.926.9027.1
  0.26%2.23.4-1.3-5263126.726.726.827.1
  1.31%2.102.166026.726.7027.1
  0.64%2021212026.926.9027.1
  0.93%20288026.826.8027.1
  1.31%1.701.755026.726.7027.1
  1.03%1.601.666026.826.8027.1
  0.88%1.601.677026.826.8027.1
  0.74%1.601.688026.926.9027.1
  1.12%1.501.555026.826.8027.1
  1.31%1.401.444026.726.7027.1
  1.05%1.40.21.245126.826.82727.1
  1.69%1.301.333026.626.6027.1
  0.93%1.201.255026.826.8027.1
  0.54%1.1-0.11.268226.826.826.827.1
  0.74%10155026.926.9027.1
  0.37%101101002727027.1
  0.37%101101002727027.1
  0.84%0.90.9004426.726.626.827.1
  1.60%0.800.822026.626.6027.1
  0.93%0.700.733026.826.8027.1
  1.31%0.700.722026.726.7027.1
  0.87%0.700.733026.826.8027.1
  1.12%0.600.622026.826.8027.1
  1.12%0.600.622026.826.8027.1
  1.12%0.600.622026.826.8027.1
  0.74%0.600.633026.926.9027.1
  1.12%0.600.622026.826.8027.1
  1.03%0.500.522026.826.8027.1
  1.03%0.500.522026.826.8027.1
  1.03%0.500.522026.826.8027.1
  1.88%0.500.511026.626.6027.1
  0.93%0.500.522026.826.8027.1
  0.93%0.500.522026.826.8027.1
  0.93%0.500.522026.826.8027.1
  0.84%0.40.10.312126.726.726.827.1
  1.69%0.400.411026.626.6027.1
  1.69%0.400.411026.626.6027.1
  0.56%0.400.433026.926.9027.1
  1.50%0.400.411026.726.7027.1
  0.75%0.40.10.312126.826.826.927.1

券商虧損排行 - 2024/03/27

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -1.69%-13.50-13.5-3003026.6026.627.1
  -0.80%-80.2-8.2-3333726.826.726.827.1
  -0.88%-6.8-0.7-6.1-2272926.826.926.827.1
  -1.41%-3.70-3.7-1001026.7026.727.1
  -0.61%-3.60.2-3.7-11112226.726.726.727.1
  -1.31%-3.50-3.5-1001026.7026.727.1
  -0.72%-2.90-2.9-1501526.9026.927.1
  -1.39%-2.60-2.6-70726.7026.727.1
  -0.88%-2.6-0.4-2.2-741126.826.826.727.1
  -0.97%-2.60-2.6-1001026.8026.827.1
  -0.90%-2.40-2.4-821026.826.826.827.1
  -1.69%-2.20-2.2-50526.6026.627.1
  -0.93%-2.20-2.2-90926.8026.827.1
  -0.74%-1.80-1.8-90926.9026.927.1
  -1.30%-1.70-1.7-50526.7026.727.1
  -0.63%-1.70.1-1.8-911026.826.826.927.1
  -0.56%-1.50-1.5-1001026.9026.927.1
  -1.12%-1.50-1.5-50526.8026.827.1
  -1.12%-1.50-1.5-50526.8026.827.1
  -0.87%-1.40-1.4-60626.8026.827.1
  -0.69%-1.30-1.3-70726.9026.927.1
  -0.60%-1.30-1.3-80826.9026.927.1
  -0.93%-1.20-1.2-50526.8026.827.1
  -0.46%-1.20-1.2-901026.926.926.927.1
  -1.12%-1.20-1.2-30426.826.926.827.1
  -0.68%-1.10-1.1-60626.9026.927.1
  -1.31%-10-1-30326.7026.727.1
  -0.74%-10-1-50526.9026.927.1
  -0.74%-10-1-40526.926.826.927.1
  -0.74%-10-1-50526.9026.927.1
  -0.62%-10-1-60626.9026.927.1
  -0.71%-0.90-0.9-50526.9026.927.1
  -1.69%-0.90-0.9-20226.6026.627.1
  -0.79%-0.80-0.8-40426.8026.827.1
  -0.79%-0.80-0.8-40426.8026.827.1
  -0.63%-0.80-0.8-50526.9026.927.1
  -0.50%-0.80-0.8-60626.9026.927.1
  -0.74%-0.80-0.8-40426.9026.927.1
  -0.74%-0.80-0.8-40426.9026.927.1
  -0.56%-0.8-0.8005526.826.926.727.1
  -0.70%-0.7-0.2-0.5-22426.826.926.827.1
  -0.93%-0.70-0.7-30326.8026.827.1
  -0.93%-0.70-0.7-30326.8026.827.1
  -0.20%-0.7-1.91.2713626.826.926.627.1
  -0.26%-0.7-0.700101026.826.826.827.1
  -0.65%-0.70-0.7-40426.9026.927.1
  -0.81%-0.60-0.6-30326.8026.827.1
  -1.12%-0.60-0.6-20226.8026.827.1
  -0.93%-0.50-0.5-20226.8026.827.1
  -0.93%-0.50-0.5-20226.8026.827.1
國光生去年營運轉虧 今年拚重回成長軌道Anue鉅亨-2024/03/13
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
國光生 相關文章